-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
foreword
On May 26, 2022, the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting Abstract was released online, in which a number of domestic CAR-T cell therapy products were unveiled, with product indications covering hematological tumors and solid tumors, and target selection Diversified, with different technical routes, the overall presentation is a 3D three-dimensional differentiated layout , showing the strong strength of the domestic CAR-T R&D pipeli.
Indications cover hematological tumors and solid tumors, with diversified target selection and different technical routes, showing a 3D three-dimensional differentiated layout as a whole
relapsed/refractory multiple myeloma
relapsed/refractory multiple myeloma
In the treatment of relapsed/refractory multiple myeloma, Yuanqi Bio's OriCAR-017 product adopts the second-generation CAR molecular design targeting GPRC5D, and adds its unique Ori element on this bas.
Compared with the new target of GPRC5D, the CAR-T combined with the old target BCMA/CD19 is also invaluable in the treatment of RR.
solid tumor
solid tumor
Claudin12 (CLDN12) is a promising therapeutic target whose expression is usually restricted to the tight junction of the gastric mucosa, but is frequently overexpressed in gastric/gastro-esophageal junction (G/GEJ) cance.
Nanjing Kaidi Biotech has constructed a novel bispecific CAR-T cell (KD-496), which can recognize both NKG2D ligand and CLDN12, and shows excellent antitumor efficacy and safety in vitro and in vivo , where the in vivo data were derived from the patient's PDX mod.
CAR-T cell therapy has shown significant clinical efficacy in hematological malignancies, but limited efficacy in solid tumo.
Malignant pleural/peritoneal mesothelioma (MPM) is an aggressive cancer characterized by poor response to therapy and poor survival, and PD-1-mediated immunosuppression has been implicated in T cell exhaustion and dysfunction in solid tumo.
Relapsed/refractory B-cell acute leukemia
Relapsed/refractory B-cell acute leukemia
CD19-targeting CAR-T cell therapy products have shown very surprising efficacy in r/r B-ALL, but some life-threatening side effects, especially high-grade cytokine release syndrome (CRS) and immune effector cells are related Neurotoxicity syndrome (ICANS) limits its widespread u.
The results show that the PrimeCAR platform can prepare CAR-T cells in a very short time, and has a high Tscm ratio, which has good safety and shows good efficacy in the treatment of r/r B-ALL at very low dos.
Cytokine release syndrome (CRS) has been a life-threatening toxic side effect since the FDA approved the first CD19 CAR-T cell therapy product (Kymriah) for the treatment of patients with r/r B-ALL, severely limiting its therapeutic potenti.
relapsed/refractory T-cell acute lymphoblastic leukemia
relapsed/refractory T-cell acute lymphoblastic leukemia
The team of Pan Jing from Beijing Boren Hospital updated the clinical data of donor-derived CD7 CAR.
Donor-derived CD7 CAR-T is very effective in the treatment of relapsed/refractory T-cell acute leukemia, but some patients will develop graft-versus-host disease (GVH.
Reference: https://conferenc.
Reference: https://conferenc.
as.
org/am/abstracts-posters